E-LIB Suche - Ergebnisse für: Bach, Peter B

1

Clinical validation of a cell-free DNA fragmentome assay fo..:

Mazzone, Peter J. ; Bach, Peter B. ; Carey, Jacob...
Cancer Discovery. , 2024

Link: https://doi.org/10.1158/..

2

Trends in financial payments from industry to US cancer cen..:

Chakraborty, Nirjhar ; Brown, Meredith ; Persaud, Sonia...
JNCI Cancer Spectrum. 8 (2024) 3 - p. , 2024

Link: https://doi.org/10.1093/..

3

Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of ..:

Leal, Alessandro I.C. ; Mathios, Dimitrios ; Jakubowski, Debbie...
CHEST. 164 (2023) 4 - p. 1019-1027 , 2023

Link: https://doi.org/10.1016/..

4

Pharmaceutical industry payments and delivery of non-recomm..:

Mitchell, Aaron P ; Dusetzina, Stacie B ; Mishra Meza, Akriti...
BMJ. , 2023

Link: https://doi.org/10.1136/..

5

Cell-free DNA approaches for cancer early detection and int..:

Medina, Jamie E ; Dracopoli, Nicholas C ; Bach, Peter B...
Journal for ImmunoTherapy of Cancer. 11 (2023) 9 - p. e006013 , 2023

Link: https://doi.org/10.1136/..

6

Reply to: Limitations of molecular testing in combination w..:

Mathios, Dimitrios ; Bach, Peter B. ; Phallen, Jillian A...
Nature Communications. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

7

Physician Payments from Pharmaceutical Companies Related to..:

Mitchell, Aaron P ; Mishra Meza, Akriti ; Trivedi, Niti U..
The Oncologist. 27 (2022) 10 - p. 857-863 , 2022

Link: https://doi.org/10.1093/..

8

Compulsory Licensing of Pharmaceuticals in High‐Income Coun..:

QUNAJ, LINDOR ; KALTENBOECK, ANNA ; BACH, PETER B.
The Milbank Quarterly. 100 (2022) 1 - p. 284-313 , 2022

Link: https://doi.org/10.1111/..

9

Compulsory Licensing of Pharmaceuticals in High-Income Coun..:

QUNAJ, LINDOR ; KALTENBOECK, ANNA ; BACH, PETER B.
The Milbank Quarterly. 100 (2022) 1 - p. 284-313 , 2022

Link: https://www.jstor.org/st..

10

Real-World Use of Bone-Modifying Agents in Metastatic Castr..:

Mitchell, Aaron P ; Meza, Akriti Mishra ; Panageas, Katherine S...
JNCI: Journal of the National Cancer Institute. , 2021

Link: https://doi.org/10.1093/..

11

Personal Payments from Pharmaceutical Companies to Authors ..:

Mitchell, Aaron P. ; Mishra, Akriti ; Dey, Pranam...
The Oncologist. 26 (2021) 9 - p. 771-778 , 2021

Link: https://doi.org/10.1002/..

12

Mapping conflict of interests: scoping review:

Chimonas, Susan ; Mamoor, Maha ; Zimbalist, Sophia A...
BMJ. , 2021

Link: https://doi.org/10.1136/..

13

Personal Payments from Pharmaceutical Companies to Authors ..:

Mitchell, Aaron P. ; Mishra, Akriti ; Dey, Pranam...
The Oncologist. 26 (2021) 10 - p. e1897-e1897 , 2021

Link: https://doi.org/10.1002/..

14

Impact of provider volume on front-line chemotherapy guidel..:

Aviki, Emeline M. ; Lavery, Jessica A. ; Long Roche, Kara...
Gynecologic Oncology. 159 (2020) 2 - p. 418-425 , 2020

Link: https://doi.org/10.1016/..

15

Commentary on Hsiue et al: Cost savings and data limitation..:

Bach, Peter B
Clinical Trials. 17 (2020) 2 - p. 126-128 , 2020

Link: https://doi.org/10.1177/..